



Press Release

## ORDINARY SHAREHOLDERS' MEETING OF FARMAE' S.P.A.

- **Appointed Giovanni Bulckaen as new director**
- **Increased the total annual remuneration of the members of the administrative body**
- **Appointed Marco Guidi as new member of the Board of Statutory Auditors**

Viareggio, 6 July 2020 – **Farmaè S.p.A.** – company listed on the AIM Italia market of Borsa Italiana, leader in Italy in the *e-retailing* of health and well-being products – announces that the ordinary Shareholders' Meeting was held today, on single call, and it approved:

1. the appointment of Giovanni Bulckaen (former Statutory Auditor of the Company) as new director - in addition to the Board of Directors, replacing Mr. Paganini - until the approval of the financial statements for the year ended December 31, 2021; Giovanni Bulckaen has declared that he meets the independence requirements provided for by law and the Company bylaws;
2. the increase in the total amount of the emoluments of the members of the administrative body, including those holding particular offices, to Euro 270,000.00 per year;
3. the appointment of Marco Guidi as new Statutory Auditor of the Company until the date of approval of the financial statements as of December 31, 2020, and to pay him an annual fee of Euro 5,000.00 for the aforementioned office.

As far as the Company is aware, neither Giovanni Bulckaen nor Marco Guidi hold, as of today, directly and/or indirectly any Farmaè ordinary shares.

Please note that the curricula vitae of Giovanni Bulckaen and of Marco Guidi can be consulted in the Governance section of the website [www.farmaegroup.it](http://www.farmaegroup.it).

It should also be noted that the summary voting report containing the number of shares represented at the Shareholders' Meeting and the shares for which votes were cast, the percentage of capital represented by such shares and the number of votes in favour and against resolutions and the number of abstentions, as well as the minutes of the Shareholders' Meeting, will be made available to the public in accordance with the procedures and timing provided for by current legislation and will be available for consultation in the Governance section ("Shareholders' Meetings - 6 July 2020") of the website [www.farmaegroup.it](http://www.farmaegroup.it).

\*\*\*

## INTEGRATION OF FINANCIAL CALENDAR

The Company announces, pursuant to Article 17 of the AIM Italia Issuers' Regulations, that it has integrated its 2020 financial calendar as follows:

DATE	EVENT
27 March 2020	Board meeting to approve the draft financial statements as of 31 December 2019
27 April 2020	Shareholder meeting to approve the financial statements as of 31 December 2019
13 July 2020	Board meeting to approve revenues data and main management indicators for the second quarter of 2020
25 September 2020	Board meeting to approve the interim financial report as of 30 June 2020
13 October 2020	Board meeting to approve revenues data and main management indicators of the third quarter of 2020

Any changes will be promptly reported to the market.

This press release is available in the Investor Relations section of the company's website [www.farmaegroup.it](http://www.farmaegroup.it).

\*\*\*

Established in Viareggio in 2014, Farmaè is the first Health and Well-being Onlife eRetailer in Italy. Onlife retail is a new economic paradigm characterised by the integration of online, offline, logistics and data in a single chain of value. The company today operates primarily in eCommerce with more than 37,000 items marketed in 10 different product categories sold, but it is also present throughout the country with 8 Farmaè stores and 1 Beautyè Store.

By sharing the new "OnLife" philosophy, Farmaè S.p.A. intends to put Customers at the centre of its business by responding immediately, rapidly and pragmatically to all their needs and ensuring a unique customer experience regardless of which sales channel is used.

For further information:

**Nomad**

Alantra Capital Markets  
+39 02 63 67 16 01  
Stefano Bellavita  
[stefano.bellavita@alantra.com](mailto:stefano.bellavita@alantra.com)

**Specialist**

Banca Profilo S.p.A.  
+39 02 584081  
Alessio Muretti  
[alessio.muretti@bancaprofilo.it](mailto:alessio.muretti@bancaprofilo.it)

**Investor Relation**

Farmaè  
Investor Relations Officer  
Alberto Maglione  
+39 0584 1660552  
[ir@farmaegroup.it](mailto:ir@farmaegroup.it)

CDR Communication srl  
IR Advisor  
Vincenza Colucci  
Tel. +39 335 6909547  
[vincenza.colucci@cdr-communication.it](mailto:vincenza.colucci@cdr-communication.it)

**Media Relation**

SEC Newgate – 02.624.999.1  
Laura Arghittu – [arghittu@segrp.com](mailto:arghittu@segrp.com)  
Federico Ferrari – 347 6456873 - [ferrari@segrp.com](mailto:ferrari@segrp.com)  
Daniele Pinosa – 335 7233872 – [pinosa@segrp.com](mailto:pinosa@segrp.com)  
Fabio Santilio – 339 8446521 [santilio@segrp.com](mailto:santilio@segrp.com)